Generic Name and Formulations:
Naloxegol 12.5mg, 25mg; tabs.
Indications for MOVANTIK:
Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation.
Discontinue all laxative therapy prior to initiation; may use as needed if suboptimal response after 3 days. Discontinue if opioid pain therapy is also discontinued. Swallow whole. Take on an empty stomach. 25mg once daily in the AM; may reduce to 12.5mg once daily if unable to tolerate. If unable to swallow tab whole: may crush and mix with 4oz of water and drink immediately; refill glass with additional 4oz of water, stir and drink. Also, may give via NG tube (see full labeling). Moderate, severe, or end-stage renal impairment (CrCl <60mL/min): 12.5mg once daily; may increase to 25 mg once daily if well tolerated and symptoms continue. Concomitant moderate CYP3A4 inhibitors: if unavoidable, reduce naloxegol to 12.5mg once daily; monitor.
Known or suspected GI obstruction. Patients at increased risk of recurrent obstruction. Concomitant strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole).
Risk of GI perforation in those with conditions associated with reduction in structural integrity of the GI tract wall (eg, peptic ulcer disease, Ogilvie’s syndrome, diverticular disease, infiltrative GI tract malignancies, or peritoneal metastases). Monitor for abdominal pain and/or diarrhea; discontinue if severe symptoms occur (consider restarting at 12.5mg once daily, if appropriate). Monitor for symptoms of opioid withdrawal (esp. patients receiving methadone or having disruptions to the blood brain barrier). Severe hepatic impairment (Child-Pugh Class C); avoid. Pregnancy. Nursing mothers: not recommended.
Opioid antagonist (peripheral).
See Contraindications. Avoid concomitant moderate CYP3A4 inhibitors (eg, diltiazem, erythromycin, verapamil): if unavoidable, reduce dose (see Adults). Avoid concomitant other opioid antagonists, grapefruit, or grapefruit juice. Concomitant strong CYP3A4 inducers (eg, rifampin, carbamazepine, St. John’s Wort): not recommended.
Abdominal pain, diarrhea, nausea, flatulence, vomiting, headache, hyperhidrosis.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- ADHD Medications Compared for Efficacy, Tolerability in Children and Adults
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Symptoms of Anxiety, Depression Differ Depending on Gender, Race, Ethnicity
- Examining Whether Adjunctive Glutamatergic Medication Further Eases OCD Symptoms
- FDA Permits Marketing of Brain Stimulation Device for OCD
- Antipsychotics Adversely Affect Adiposity and Insulin Sensitivity in Youths
- Know Before You Go: Practicing Medicine Abroad